Nutritional interventions in the framework of a person-centered model of health care and geroprotection

Abstract

The existing system of prevention of age-related diseases that focused on cohort-based risk factors shows insufficient effectiveness; thus, practicable methodology of health promotion compliant with the principles of P4 medicine, with a special focus on nutritional interventions, is needed. The study outlines an algorithm of nutritional interventions designed in accordance with the principles of person-centered organizational model of healthcare. The algorithm is based on the modern concept of exposome and its influence on the key mechanisms of accelerated aging and pathogenesis of age-related diseases. The proposed approach to personalized nutritional interventions is implemented in three steps: (1) the need for nutritional intervention is identified through the evaluation of the signs and symptoms of health impairment and accelerated aging that have very probable association with suboptimal nutrition, (2) individual exposome factors are evaluated as potential sources of health problems, and (3) first-line nutritional interventions are selected and implemented. The algorithm focused on eliminating the shortcomings of the diagnosis-centered organizational model of healthcare prevailing worldwide: to enable early detection of distress, use of the most effective and affordable interventions (diet and nutrition), and maximum involvement of the patient in health management. The algorithm bears a good potential of automation through decision support for patients regarding health. The use of original questionnaires and patient-centered data reduces the cost and expands the possibilities of scaling the algorithms of intervention. The algorithm can become the basis for the wide introduction of the principles of predictive, personalized, and participatory prevention of age-related diseases.

Keywords

age-related diseases / prevention / nutrition / exposome / person-centered model / P4 medicine

References

[1] Order of the Ministry of Health of Russia No. 186 of 24 April 2018 “Ob utverzhdenii Kontseptsii prediktivnoy, preventivnoy i personalizirovannoy meditsiny”. Available from: https://www.garant.ru/products/ipo/prime/doc/71847662/. (In Russ).

[2] Приказ Минздрава России № 186 от 24 апреля 2018 г. «Об утверждении Концепции предиктивной, превентивной и персонализированной медицины». Режим доступа: https://www.garant.ru/products/ipo/prime/doc/71847662/. Дата обращения: 12.10.2022.

[3] López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi: 10.1016/j.cell.2013.05.039

[4] López-Otín C., Blasco M.A., Partridge L., et al. The hallmarks of aging // Cell. 2013. Vol. 153, N 6. P. 1194–1217. doi: 10.1016/j.cell.2013.05.039

[5] López-Otín C, Kroemer G. Hallmarks of Health. Cell. 2021; 184(1):33–63. doi: 10.1016/j.cell.2020.11.034

[6] López-Otín C., Kroemer G. Hallmarks of Health // Cell. 2021. Vol. 184, N 1. P. 33–63. doi: 10.1016/j.cell.2020.11.034

[7] Kahl KG, Stapel B, Frieling H. Link between depression and cardiovascular diseases due to epigenomics and proteomics: Focus on energy metabolism. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:146–157. doi: 10.1016/j.pnpbp.2018.09.004

[8] Kahl K.G., Stapel B., Frieling H. Link between depression and cardiovascular diseases due to epigenomics and proteomics: Focus on energy metabolism // Prog Neuropsychopharmacol Biol Psychiatry. 2019. Vol. 89. P. 146–157. doi: 10.1016/j.pnpbp.2018.09.004

[9] Wild CP. Complementing the genome with an “exposome”: The outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prevention. 2005;14(8):1847–1850. doi: 10.1158/1055-9965.EPI-05-0456

[10] Wild C.P. Complementing the genome with an “exposome”: The outstanding challenge of environmental exposure measurement in molecular epidemiology // Cancer Epidemiol Biomarkers Prevention. 2005. Vol. 14, N 8. P. 1847–1850. doi: 10.1158/1055-9965.EPI-05-0456

[11] Wild CP. The exposome: from concept to utility. Int J Epidemiol. 2012;41(1):24–32. doi: 10.1093/ije/dyr236

[12] Wild C.P. The exposome: from concept to utility // Int J Epidemiol. 2012. Vol. 41, N 1. P. 24–32. doi: 10.1093/ije/dyr236

[13] Kalia V, Belsky DW, Baccarelli AA, Miller GW. An exposomic framework to uncover environmental drivers of aging. Exposome. 2022;2(1):osac002. doi: 10.1093/exposome/osac002

[14] Kalia V., Belsky D.W., Baccarelli A.A., Miller G.W. An exposomic framework to uncover environmental drivers of aging // Exposome. 2022. Vol. 2, N 1. P. osac002. doi: 10.1093/exposome/osac002

[15] Poveda A, Pomares-Millan H, Chen Y, et al. Exposome-wide ranking of modifiable risk factors for cardiometabolic disease traits. Sci Rep. 2022;12(1):4088. doi: 10.1038/s41598-022-08050-1

[16] Poveda A., Pomares-Millan H., Chen Y., et al. Exposome-wide ranking of modifiable risk factors for cardiometabolic disease traits // Sci Rep. 2022. Vol. 12, N 1. P. 4088. doi: 10.1038/s41598-022-08050-1

[17] Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens). 2009;8(1):7–22. doi: 10.14310/horm.2002.1217

[18] Epel E.S. Psychological and metabolic stress: a recipe for accelerated cellular aging? // Hormones (Athens). 2009. Vol. 8, N 1. P. 7–22. doi: 10.14310/horm.2002.1217

[19] Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev. 2010;35(1):2–16. doi: 10.1016/j.neubiorev.2009.10.002

[20] Juster R.P., McEwen B.S., Lupien S.J. Allostatic load biomarkers of chronic stress and impact on health and cognition // Neurosci Biobehav Rev. 2010. Vol. 35, N 1. P. 2–16. doi: 10.1016/j.neubiorev.2009.10.002

[21] Fava GA, McEwen BS, Guidi J, et al. Clinical characterization of allostatic overload. Psychoneuroendocrinology. 2019;108:94–101. doi: 10.1016/j.psyneuen.2019.05.028

[22] Fava G.A., McEwen B.S., Guidi J., et al. Clinical characterization of allostatic overload // Psychoneuroendocrinology. 2019. Vol. 108. P. 94–101. doi: 10.1016/j.psyneuen.2019.05.028

[23] Picard M, McEwen BS. Psychological Stress and Mitochondria: A Conceptual Framework. Psychosom Med. 2018;80(2):126–140. doi: 10.1097/PSY.0000000000000544

[24] Picard M., McEwen B.S. Psychological Stress and Mitochondria: A Conceptual Framework // Psychosom Med. 2018. Vol. 80, N 2. P. 126–140. doi: 10.1097/PSY.0000000000000544

[25] Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl. 1):S4–9. doi: 10.1093/gerona/glu057

[26] Franceschi C., Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases // J Gerontol A Biol Sci Med Sci. 2014. Vol. 69, suppl. 1. P. S4–9. doi: 10.1093/gerona/glu057

[27] Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505–522. doi: 10.1038/s41569-018-0064-2

[28] Ferrucci L., Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty // Nat Rev Cardiol. 2018. Vol. 15, N 9. P. 505–522. doi: 10.1038/s41569-018-0064-2

[29] Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12): 1822–1832. doi: 10.1038/s41591-019-0675-0

[30] Furman D., Campisi J., Verdin E., et al. Chronic inflammation in the etiology of disease across the life span // Nat Med. 2019. Vol. 25, N 12. P. 1822–1832. doi: 10.1038/s41591-019-0675-0

[31] Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607. doi: 10.2337/diab.37.12.1595

[32] Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease // Diabetes. 1988. Vol. 37, N 12. P. 1595–1607. doi: 10.2337/diab.37.12.1595

[33] Crofts CAP, Zinn C, Wheldon M, Schofield G. Hyperinsulinemia: A unifying theory of chronic disease? Diabesity. 2015;1(4):34–43. doi: 10.15562/diabesity.2015.19

[34] Crofts C.A.P., Zinn C., Wheldon M., Schofield G. Hyperinsulinemia: A unifying theory of chronic disease? // Diabesity. 2015. Vol. 1, N 4. P. 34–43. doi: 10.15562/diabesity.2015.19

[35] Janssen JAMJL. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. Int J Mol Sci. 2021;22(15):7797. doi: 10.3390/ijms22157797

[36] Janssen J.A.M.J.L. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer // Int J Mol Sci. 2021. Vol. 22, N 15. P. 7797. doi: 10.3390/ijms22157797

[37] Martyushev-Poklad AV, Yankevich DS, Petrova MV, Savitskaya NG. Hyperinsulinemia and age-related diseases: interrelations and approaches to treatment. Problems of Nutrition. 2022;91(3):21–31. (In Russ). doi: 10.33029/0042-8833-2022-91-3-21-31

[38] Мартюшев-Поклад А.В., Янкевич Д.С., Петрова М.В., Савицкая Н.Г. Гиперинсулинемия и возрастзависимые заболевания: взаимосвязь и подходы к лечению // Вопросы питания. 2022. Т. 91, № 3. С. 21–31. doi: 10.33029/0042-8833-2022-91-3-21-31

[39] Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58(4):495–505. doi: 10.1002/ana.20624

[40] Beal M.F. Mitochondria take center stage in aging and neurodegeneration // Ann Neurol. 2005. Vol. 58, N 4. P. 495–505. doi: 10.1002/ana.20624

[41] Lane RK, Hilsabeck T, Rea SL. The role of mitochondrial dysfunction in age-related diseases. Biochim Biophys Acta. 2015; 1847(11):1387–1400. doi: 10.1016/j.bbabio.2015.05.021

[42] Lane R.K., Hilsabeck T., Rea S.L. The role of mitochondrial dysfunction in age-related diseases // Biochim Biophys Acta. 2015. Vol. 1847, N 11. P. 1387–1400. doi: 10.1016/j.bbabio.2015.05.021

[43] Haas RH. Mitochondrial Dysfunction in Aging and Diseases of Aging. Biology (Basel). 2019;8(2):48. doi: 10.3390/biology8020048

[44] Haas R.H. Mitochondrial Dysfunction in Aging and Diseases of Aging // Biology (Basel). 2019. Vol. 8, N 2. P. 48. doi: 10.3390/biology8020048

[45] Martyushev-Poklad AV, Guliev YaI, Kazakov IF, et al. Person-centered instruments in digital transformation of healthcare: ways to improve. Medical Doctor and Information Technology. 2021;(S5):4–13. (In Russ.)

[46] Мартюшев-Поклад А.В., Гулиев Я.И., Казаков И.Ф., и др. Персоноцентрированные инструменты цифровой трансформации здравоохранения: пути совершенствования // Врач и информационные технологии. 2021. № S5. С. 4–13.

[47] Martyushev-Poklad A, Yankevich D, Petrova M. Improving the Effectiveness of Healthcare: Diagnosis-Centered Care Vs. Person-Centered Health Promotion, a Long Forgotten New Model. Front Public Health. 2022;10:819096. doi: 10.3389/fpubh.2022.819096

[48] Martyushev-Poklad A., Yankevich D., Petrova M. Improving the Effectiveness of Healthcare: Diagnosis-Centered Care Vs. Person-Centered Health Promotion, a Long Forgotten New Model // Front Public Health. 2022. Vol. 10. P. 819096. doi: 10.3389/fpubh.2022.819096

[49] Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018; 34(2):71–80. doi: 10.1097/MOG.0000000000000423

[50] Di Ciaula A., Wang D.Q., Portincasa P. An update on the pathogenesis of cholesterol gallstone disease // Curr Opin Gastroenterol. 2018. Vol. 34, N 2. P. 71–80. doi: 10.1097/MOG.0000000000000423

[51] Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability — a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189. doi:10.1186/s12876-014-0189-7

[52] Bischoff S.C., Barbara G., Buurman W., et al. Intestinal permeability — a new target for disease prevention and therapy // BMC Gastroenterol. 2014. Vol. 14. P. 189. doi: 10.1186/s12876-014-0189-7

[53] Pfau ML, Ménard C, Russo SJ. Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities. Annu Rev Pharmacol Toxicol. 2018;58:411–428. doi: 10.1146/annurev-pharmtox-010617-052823

[54] Pfau M.L., Ménard C., Russo S.J. Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities // Annu Rev Pharmacol Toxicol. 2018. Vol. 58. P. 411–428. doi: 10.1146/annurev-pharmtox-010617-052823

[55] Lukaczer D. Chapter 28. Clinical approaches to gastrointestinal imbalance. The “4R” program. In: Jones D, Quinn S, editors. Textbook of Functional Medicine. Gig Harbor, WA: Institute for Functional Medicine; 2005. P:462–468.

[56] Lukaczer D. Chapter 28. Clinical approaches to gastrointestinal imbalance. The “4R” program. In: Jones D., Quinn S., editors. Textbook of Functional Medicine. Gig Harbor, WA: Institute for Functional Medicine, 2005. P. 462–468.

[57] Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim Sci J. 2020;91(1):e13357. doi: 10.1111/asj.13357

[58] Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions // Anim Sci J. 2020. Vol. 91, N 1. P. e13357. doi: 10.1111/asj.13357

[59] Fortea M, Albert-Bayo M, Abril-Gil M, et al. Present and Future Therapeutic Approaches to Barrier Dysfunction. Front Nutr. 2021;8:718093. doi: 10.3389/fnut.2021.718093

[60] Fortea M., Albert-Bayo M., Abril-Gil M., et al. Present and Future Therapeutic Approaches to Barrier Dysfunction // Front Nutr. 2021. Vol. 8. P. 718093. doi: 10.3389/fnut.2021.718093

[61] Lepeshkova TS, Beltyukov EK, Naumova VV, et al. Food allergy. Diagnosis, treatment and prevention. Ekaterinburg: USMU; 2021. 113 p. (In Russ).

[62] Лепешкова Т.С., Бельтюков Е.К., Наумова В.В., и др. Пищевая аллергия. Диагностика, лечение и профилактика. Екатеринбург: УГМУ, 2021. 113 с.

[63] Damas OM, Garces L, Abreu MT. Diet as Adjunctive Treatment for Inflammatory Bowel Disease: Review and Update of the Latest Literature. Curr Treat Options Gastroenterol. 2019;17(2):313–325. doi: 10.1007/s11938-019-00231-8

[64] Damas O.M., Garces L., Abreu M.T. Diet as Adjunctive Treatment for Inflammatory Bowel Disease: Review and Update of the Latest Literature // Curr Treat Options Gastroenterol. 2019. Vol. 17, N 2. P. 313–325. doi: 10.1007/s11938-019-00231-8

[65] Campmans-Kuijpers MJE, Dijkstra G. Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID). Nutrients. 2021;13(4):1067. doi: 10.3390/nu13041067

[66] Campmans-Kuijpers M.J.E., Dijkstra G. Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID) // Nutrients. 2021. Vol. 13, N 4. P. 1067. doi: 10.3390/nu13041067

[67] Konijeti GG, Kim N, Lewis JD, et al. Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23(11):2054–2060. doi: 10.1097/MIB.0000000000001221

[68] Konijeti G.G., Kim N., Lewis J.D., et al. Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease // Inflamm Bowel Dis. 2017. Vol. 23, N 11. P. 2054–2060. doi: 10.1097/MIB.0000000000001221

[69] Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517–1527. doi: 10.1136/gutjnl-2017-313750

[70] Staudacher H.M., Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS // Gut. 2017. Vol. 66, N 8. P. 1517–1527. doi: 10.1136/gutjnl-2017-313750

[71] Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016;229(2):R67–81. doi: 10.1530/JOE-15-0533

[72] Cleasby M.E., Jamieson P.M., Atherton P.J. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities // J Endocrinol. 2016. Vol. 229, N 2. P. R67–81. doi: 10.1530/JOE-15-0533

RIGHTS & PERMISSIONS

Eco-Vector